Ipamorelin vs GHRP-6
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: Growth Hormone Releasing Peptide 6, SKF-110679
GHRP-6 is a synthetic six-amino-acid peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) that tricks the body into releasing its own growth hormone. It was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. It has no approval as a drug anywhere and is used only as a research compound.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- These GH secretagogues are frequently combined to enhance growth hormone release.
Detailed Comparison
| Attribute | Ipamorelin | GHRP-6 |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | GHRP-6 binds and activates the growth hormone secretagogue receptor type 1a (GHS-R1a), the same receptor later found to be the natural target of the hunger hormone ghrelin. When it switches that receptor on in the pituitary and hypothalamus, the pituitary fires off a pulse of growth hormone. Because GHS-R1a also sits on appetite-driving neurons in the brain (the NPY/AgRP cells of the arcuate nucleus), GHRP-6 is a strong appetite stimulant, more so than the other GHRPs. At higher doses it also nudges up cortisol and prolactin, since the receptor system is not perfectly selective for the GH pathway. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | 100-300 mcg 2-3x daily 2-3x daily |
| Administration | Subcutaneous injection | Subcutaneous injection, ideally fasted |
| Typical Duration | 8-12 weeks typical | 8-12 weeks |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | GHRP-6 has been studied in humans, but mostly as a lab and diagnostic probe rather than as a treatment with large clinical trials behind it. Early work in the 1980s and 1990s showed it reliably triggers growth hormone release, and chasing its mechanism is literally what led Kojima and colleagues to discover ghrelin in 1999, which reframed how we understand hunger and GH control. A 2013 pharmacokinetic study in nine healthy men found oral bioavailability under 1 percent and an elimination half-life around 2.5 hours, which is why it is given by injection. The popular claims about muscle gain, fat loss, and healing in fitness circles are not backed by controlled human outcome trials. It is not approved by the FDA or EMA for any use and remains a research chemical, with appetite stimulation, water retention, and cortisol/prolactin bumps as known effects. |
Frequently Asked Questions: Ipamorelin vs GHRP-6
What is the difference between Ipamorelin and GHRP-6?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. GHRP-6 is a growth hormone peptide that ghrp-6 is a synthetic six-amino-acid peptide (his-d-trp-ala-trp-d-phe-lys-nh2) that tricks the body into releasing its own growth hormone. it was one of the first growth hormone secretagogues ever made, and the hunt to find out why it worked led scientists straight to the discovery of ghrelin. it has no approval as a drug anywhere and is used only as a research compound. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or GHRP-6?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while GHRP-6 is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and GHRP-6 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and GHRP-6 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.